Navigation Links
Product Shifts are Occurring in the Renal Anemia and Bone and Mineral Metabolism Markets According to the Most Recent TreatmentTrends(R): US Nephrology Report from BioTrends Research Group
Date:4/27/2009

EXTON, Pa., April 27 /PRNewswire/ -- BioTrends Research Group, Inc. released TreatmentTrends(R): US Nephrology, a syndicated report based on online survey results from over 200 US Nephrologists.

In the ESA market, changes that have occurred seem to have taken place at the product level, while the overall use of ESAs has remained stable compared to the same period last year. Among patients with Chronic Kidney Disease not on dialysis (CKD), market share for Ortho Biotech's Procrit has been trending upward compared to the first quarter of 2008, primarily at the expense of Amgen's Aranesp. And while only about one-third of Nephrologists report that managed care policies have led to a decreased use of ESAs, Aranesp seems to be more negatively impacted by managed care than Procrit.

There have been no significant changes in the use of IV iron in the past year although Nephrologists project significant increases in the use of IV iron among CKD patients in the next three months. American Regent's Venofer continues to hold the position as market leader among CKD patients. In the hemodialysis market, use of Watson's Ferrlecit decreased while Fresenius Medical Care's Venofer, the market leader, experienced share growth year over year. The greatest share growth came from Nephrologists primarily affiliated with FMC. Nephrologists continue to await the approval of AMAG's Feraheme and familiarity with the product is on the rise.

Product shifts have also been the theme in the phosphate binder market where use of Genzyme's Renvela continues to take hold primarily at the expense of Genzyme's Renagel, although the move away from calcium-based binders in both dialysis and CKD continues. Close to 90% of Nephrologists report having at least some hemodialysis patients on Renvela compared to 67% in the previous quarter. Sevelamer is the market leader in dialysis with 55% share. Among CKD patients, sevelamer and FMC's PhosL
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Physician Skin Care Specialist Says Proposed New Rules for Sunscreen Products Will Better Protect the Public
3. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
4. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
5. End-to-End HR Performance Benchmarks: Metrics That Will Help Turn the HR Cost Center into a Productivity Driver
6. Boston Micromachines Multi-DM Named One of the Years Most Innovative Products
7. Drug Detection Kits Manufactured By IDenta Corp. Shown During French Television Broadcast (at TF1) - Product Aids French Police In Bust of 600 Kilograms Of Cocaine
8. Why Are Most Health & Wellness Products Doomed to Failure?
9. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
10. GladRags Introduces the Moon Cup - An Environmentally-Sound and Safe Alternative to Disposable Feminine Hygiene Products!
11. OneBeacon Professional Partners to Offer Podiatrist Medical Malpractice Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation ... therapy caused strokes, heart attacks, and other injuries in ... F. Kennelly as the transferee judge and ordered what ... federal court. , As one of his first organizing ... of attorneys who will move the litigation forward on ...
(Date:8/1/2014)... central role in regulating appetite and whole-body metabolism. A ... control of food intake and body weight, but the ... unclear. A new study in the ... in a type of neuron known as pro-opiomelanocortin (POMC) ... diet. Sabrina Diano and colleagues at Yale University ...
(Date:8/1/2014)... 2014 Stryker hip lawsuits ( ... 2012 Rejuvenate and ABG II Modular-Neck Hip Stem ... Bergen County Superior Court, Bernstein Liebhard LLP reports. ... Court has issued a Final Amended Stipulated ... hard copy and electronic materials produced by any ...
(Date:8/1/2014)... CLEVELAND, Ohio In a first-of-its-kind study, researchers at ... found that lap infants may be at greater risk ... analyzed pediatric medical emergencies on flights worldwide between January ... deaths occurred in children under the age of 2. ... MedAire to characterize the rare event of an in-flight ...
(Date:8/1/2014)... Vegas, NV (PRWEB) August 01, 2014 ... and opportunities for independent community pharmacies. At ThoughtSpot ... pharmacists are equipped with practices and resources to ... Session, AmerisourceBergen leaders focused on critical issues to ... learn, optimize and grow. , ThoughtSpot show ...
Breaking Medicine News(10 mins):Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5
... "Thomson Reuters Citation Laureates" Recognized for Their,Contributions to ... Oct. 1 The Scientific business,of Thomson Reuters ... researchers likely to be in contention for Nobel ... winners to be announced in October., Each ...
... of serious public health issue through first ... Sudden cardiac arrest (SCA) claims,more lives each year ... a new Heart Rhythm Society survey, four out of ... health issue that causes,more than 250,000 deaths each year. ...
... developed a method of using nanoparticles to deliver treatments ... team led by Richard Borgens of the School of ... of Biomedical Engineering coated silica nanoparticles with a polymer ... That research is being published in the October edition ...
... Recession Fears - List Reports Aggregate Revenue of $185 Billion; Nuclear ... 100 Health Companies and No. 1161 on the Inc. 5000 With ... ... (PRWEB) October 1, 2008 -- Inc. today ranked www.mobilenuclear.com [Nuclear Medicine ...
... Ticker Symbol: CUR, QUEBEC CITY, Oct. 1 ... company commercializing high-value cancer diagnostic,tests and delivering laboratory ... CEO of the Company, will be presenting a ... Focus Conference on,Monday, October 6, 2008, at 1:30 ...
... with No Monthly ... Premium, ... serving seniors and others with Medicare,announced today that its new Medicare Advantage ... with no monthly plan premiums and no deductibles., "Access to affordable, ...
Cached Medicine News:Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 2Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 3Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 4Health News:The Scientific Business of Thomson Reuters Predicts Nobel Laureates 5Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 2Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 3Health News:New Research: Americans Underestimate Dangers of Sudden Cardiac Arrest 4Health News:Researchers use nanoparticles to deliver treatment for brain, spinal cord injuries 2Health News:America's 5000 Fastest-Growing Private Companies Revealed 2Health News:DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008 2Health News:SCAN Health Plan Arizona Announces Its 2009 MAPD Benefits for Maricopa County 2
(Date:7/31/2014)...  ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2014.  Revenue for the quarter was $415.2 ... (a 1 percent decrease on a constant currency basis). Net ... to the quarter ended June 30, 2013. Diluted earnings per ... percent compared to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... Calif., July 31, 2014 Pharmacyclics, Inc. (the "Company") ... recent developments for the quarter ended June 30, 2014. ... June 30, 2014 Revenue Total revenue for the quarter ... million for the quarter ended June 30, 2013 primarily due ... million. Total revenue for the six months ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Contaminated with Diethylene Glycol,(DEG) Remains a Potential ... Md., May 4, 2007-The U.S. Food and ... repackers, and health professionals who compound,medications to ... a,sweetener commonly used worldwide in liquid over-the-counter ...
... ROCKVILLE, Md., April 25, 2007-The U.S. Food ... a Consent Decree of,Permanent Injunction against PharmaFab ... officials, Mark Tengler, PharmaFab's president,and Russ McMahen, ... the illegal manufacture and distribution of prescription ...
Cached Medicine Technology:FDA Advises Manufacturers to Test Glycerin for Possible,Contamination 2Major Manufacturer of Unapproved and Adulterated Drugs 2Major Manufacturer of Unapproved and Adulterated Drugs 3
... Slimline single-use pH catheters are ... cross-contamination and allow greater patient comfort ... ,Medtronic pH measurement systems have been ... that allow an accurate room-temperature calibration. ...
FLEXILOG spare part....
FLEXILOG spare part....
Complete calibration kits are available for both pH and manometry systems....
Medicine Products: